Solid Biosciences Inc (NASDAQ:SLDB) Receives $9.83 Average PT from Analysts
Shares of Solid Biosciences Inc (NASDAQ:SLDB) have been given an average rating of “Hold” by the ten brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.83.
Several brokerages have recently issued reports on SLDB. Credit Suisse Group reduced their price target on Solid Biosciences from $6.00 to $2.00 and set a “hold” rating for the company in a report on Tuesday, November 12th. Zacks Investment Research downgraded Solid Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Svb Leerink raised shares of Solid Biosciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $8.00 to $15.00 in a research report on Monday, August 19th. Leerink Swann raised shares of Solid Biosciences from a “market perform” rating to an “outperform” rating in a research report on Monday, August 19th. Finally, Evercore ISI initiated coverage on shares of Solid Biosciences in a research report on Friday, October 11th. They issued an “outperform” rating and a $22.00 target price for the company.
SLDB stock traded up $0.33 during mid-day trading on Tuesday, hitting $4.66. The stock had a trading volume of 750,459 shares, compared to its average volume of 721,943. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.05. Solid Biosciences has a 1-year low of $2.75 and a 1-year high of $32.85. The company has a fifty day moving average of $7.93 and a 200 day moving average of $7.34. The stock has a market capitalization of $204.65 million, a price-to-earnings ratio of -2.07 and a beta of 1.38.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Read More: How to Invest in Marijuana Stocks
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.